Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HFB200603 |
Synonyms | |
Therapy Description |
HFB200603 is a monoclonal antibody that targets BTLA, which potentially decreases tumor immune suppression (Cancer Res 2022;82(12_Suppl):Abstract nr 4248). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HFB200603 | HFB-200603|HFB 200603 | HFB200603 is a monoclonal antibody that targets BTLA, which potentially decreases tumor immune suppression (Cancer Res 2022;82(12_Suppl):Abstract nr 4248). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05789069 | Phase I | HFB200603 HFB200603 + Tislelizumab | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |